Metformin Extended Release 500mg and 750mg Recall – Teva/Actavis

June 03, 2020

After notification of any recall, Express Scripts will continue processing new and refill prescriptions with product from non-recalled lots or manufacturers, if available.

Teva Pharmaceuticals is voluntarily recalling 14 lots of Metformin Hydrochloride Extended-Release Tablets, USP 500mg and 750mg distributed in the United States under the Actavis Pharma label. Teva was notified by the U.S. Food and Drug Administration that 14 lots of Metformin Hydrochloride Extended-Release Tablets were tested and showed results for NDMA, an unexpected impurity, at levels in excess of acceptable limits and recommended recall of the fourteen tested lots.

Additional information, including the impacted lots, is available on the FDA’s website: https://www.fda.gov/safety/recalls-market-withdrawals-safety-alerts/teva-pharmaceuticals-usa-inc-initiates-voluntary-nationwide-recall-metformin-hydrochloride-extended

What do I need to know?

  • Express Scripts will mail letters to patients who have received medication impacted by the recall detailing.
  • The Food and Drug Administration has stated that patients who have the recalled medicine should continue taking it until they have a new supply unless otherwise directed by their healthcare provider, as the risk of harm to the your health may be higher if the treatment is stopped immediately without any alternative treatment.

    • Please consult with your prescriber for guidance on continuing to take this medication or if you should obtain a new prescription for an alternative therapy.
    • If you and your prescriber decide you should continue to take the medication on hand, your next fill will be processed using medication that is not part of any existing recall.
    • If you choose to stay on this therapy but need to obtain a fresh supply and it is not time for your next refill, please call us at the toll free number on your prescription bottle to request an early refill. Your order will be filled with medication that is not part of any existing recall.
  • It is important to note that your home delivery pharmacy will NOT be accepting returns or providing credit for these recalled products.
  • Questions regarding the return of any remaining product in your possession should be directed to Teva/Actavis’s product recall processor, Inmar at 855-532-1850 (Monday through Friday, 9:00 am to 5:00 pm Eastern Time) or email Inmar at tevarecalls@inmar.com

Why was this medication recalled?

  • This voluntary recall is being issued by Teva working with the FDA because an impurity N-Nitrosodimethylamine (NDMA) was detected in the identified lots.
  • Any suspected adverse events that may be related to the use of these products should be reported to your prescriber. You can also report adverse events that may be related to this recall to FDA's Med Watch Program either online, by regular mail or by fax.
  • Online: https://www.accessdata.fda.gov/scripts/medwatch/index.cfm?action=reporting.home
  • Regular Mail: Use postage-paid, pre-addressed Form FDA 3500B available at: www.fda.gov/MedWatch/getforms.htm. Mail to the address on the pre-addressed form.
  • Fax: 1-800-332-0178 (toll free)

Last updated: August 28, 2020

The information on this site is not intended to take the place of your doctor or other healthcare professionals. It is a resource to help you make the best decisions and get the most from the medical services available to you. A licensed physician should be consulted for diagnosis and treatment of all medical conditions.